In HGH research, two distinct classes of compounds are used to stimulate growth hormone secretion: GHRH analogues (Growth Hormone-Releasing Hormone analogues) and GHRPs (Growth Hormone-Releasing Peptides). These are fundamentally different molecules acting through completely different receptors, and understanding their distinction is essential for interpreting research in this field.
The Two Receptor Pathways
The pituitary somatotroph — the cell that makes and releases HGH — has two primary stimulatory inputs that can drive HGH secretion:
| Item | Detail |
| GHRH receptor (GHRHR) | Activated by GHRH from hypothalamus and GHRH analogues like CJC-1295 and Mod GRF(1-29) |
| Ghrelin receptor (GHSR) | Activated by ghrelin (from stomach) and synthetic GHRPs like Ipamorelin, GHRP-2, GHRP-6 |
These two receptor systems operate through different intracellular signalling pathways — GHRHR primarily through cAMP/PKA, GHSR primarily through phospholipase C/IP3/calcium signalling — and their downstream effects on somatotroph function, while both ultimately driving HGH release, have distinct characteristics.
GHRH Analogues: Mechanism and Characteristics
GHRH analogues mimic the endogenous hypothalamic signal that drives HGH secretion. The native GHRH(1-44) peptide is rapidly degraded by DPP-IV through cleavage of the alanine at position 2. Research analogues address this by substituting the position 2 amino acid with DPP-IV-resistant alternatives.
GHRH receptor activation drives adenylyl cyclase activity, increasing cAMP in somatotrophs. This cAMP signal activates PKA, which phosphorylates transcription factors driving HGH gene expression and sensitises the vesicular release machinery to calcium-triggered exocytosis. The result is HGH synthesis and release.
A key characteristic of GHRH-only stimulation is its strong inhibition by somatostatin. When somatostatin tone is high (as it naturally is between hypothalamic pulses, and increasingly with age), GHRH stimulation produces minimal HGH response. This somatostatin-sensitivity is both a limitation and a feature — it means GHRH analogue activity is constrained within the normal regulatory architecture.
GHRPs: Mechanism and Characteristics
GHRPs act through the ghrelin receptor (GHSR), a receptor discovered after the synthetic GHRPs that activated it. Ghrelin — the stomach-derived ‘hunger hormone’ — was eventually identified as the endogenous GHSR ligand, with synthetic GHRPs serving as laboratory tools that preceded and enabled the receptor’s characterisation.
GHSR activation in somatotrophs triggers phospholipase C activity, generating IP3 and diacylglycerol (DAG). IP3 releases calcium from intracellular stores, and DAG activates protein kinase C. The resulting calcium transient directly triggers HGH vesicle exocytosis — a more immediate release mechanism than the cAMP pathway activated by GHRH.
Critically, GHSR activation also has hypothalamic effects: it increases GHRH neuron firing (amplifying the endogenous GHRH signal) and inhibits somatostatin release (removing the brake on HGH secretion). This hypothalamic component means GHRPs can stimulate HGH release even when somatostatin tone would otherwise suppress GHRH-driven secretion.
The Synergy Rationale
Research has consistently documented that combining a GHRH analogue with a GHRP produces HGH responses substantially larger than either compound alone — not simply additive, but synergistic. In some research models, the combined HGH response has been 10-20 times larger than either compound produces independently.
The mechanistic basis for this synergy involves several complementary effects: GHRP reduces somatostatin inhibition, making somatotrophs more responsive to GHRH stimulation; GHRP increases hypothalamic GHRH output, amplifying the GHRH analogue’s signal; the two receptors’ different intracellular pathways (cAMP and calcium) converge on HGH release through independent mechanisms; and GHRH analogue stimulation upregulates GHSR expression on somatotrophs, enhancing the cell’s responsiveness to GHRP.
Comparison of Key Research Compounds
| Item | Detail |
| CJC-1295 (DAC) | GHRH analogue | GHRHR | ~6-8 days | Sustained GH axis stimulation |
| Mod GRF(1-29) | GHRH analogue | GHRHR | ~30 min | Acute GH pulse research |
| Ipamorelin | GHRP | GHSR | ~2 hours | Selective GH pulse, low cortisol |
| GHRP-2 | GHRP | GHSR | ~1-2 hours | Strong GH stimulation, some cortisol |
| GHRP-6 | GHRP | GHSR | ~1-2 hours | Potent but significant cortisol elevation |
| Hexarelin | GHRP | GHSR | ~1-2 hours | Most potent GHRP, cardiac research interest |
GHRH analogues and GHRPs are not interchangeable — they are complementary tools targeting different receptors with different downstream effects. Understanding which receptor you’re targeting, and why, is the foundation of productive GH axis research design.